Substantial combination benefit of targeting both the ANGPT2 and VEGFA pathways has been demonstrated preclinically. Angiopoietins (ANGPTs) are ligands of the endothelial cell receptor TIE2 and ...

F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this ...